Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Authors

H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-Bouvet, K. Zaman, E. Matos, T. Petit, A. Bodmer, N. Quenel-Tueux, C. Chakiba, P. Vuylsteke, G. Jerusalem, E. Brain, O. Tredan, C.G.M. Messina, L. Slaets, D. Cameron